Literature DB >> 11709723

Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.

S G Brodie1, X Xu, W Qiao, W M Li, L Cao, C X Deng.   

Abstract

Germline mutations in the tumor suppressor gene BRCA1 predispose women to breast cancer, however somatic mutations in the gene are rarely detected in sporadic cancers. To understand this phenomenon, we examined mouse models carrying conditional disruption of Brca1 in mammary epithelium in either p53 wild type (wt) or heterozygous backgrounds. Although a p53(+/-) mutation significantly accelerated tumorigenesis, both strains developed mammary tumors in a stochastic fashion, suggesting that multiple factors, in addition to p53 mutations, may be involved in Brca1 related tumorigenesis. A unique feature of Brca1 mammary tumors is their highly diverse histopathology accompanied by severe chromosome abnormalities. The tumors also display extensive genetic/molecular alterations, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1 in the majority of tumors, while they were virtually ERalpha and p16 negative. Translocations involving p53 were also identified which lead to abnormal RNA and protein products. In addition, we generated cell lines from mammary tumors and found that the cells retained many of the genetic changes found in the primary tumors, suggesting that these genes may be players in Brca1-associated tumorigenesis. Despite their distinct morphology, all cultured tumor cells were Tamoxifen resistant but highly sensitive to Doxorubicin or gamma-irradiation, suggesting that these methods would be effective in treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709723     DOI: 10.1038/sj.onc.1204929

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  82 in total

1.  CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Authors:  Eun-Hee Kim; Chuxia Deng; Michael B Sporn; Darlene B Royce; Renee Risingsong; Charlotte R Williams; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-20

2.  Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system.

Authors:  Xavier Coumoul; Wenmei Li; Rui-Hong Wang; Chuxia Deng
Journal:  Nucleic Acids Res       Date:  2004-06-15       Impact factor: 16.971

Review 3.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

4.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

5.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09

Review 6.  Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.

Authors:  Elizabeth A Musgrove; Elizabeth A Davison; Christopher J Ormandy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

Authors:  Yongxian Ma; Pragati Katiyar; Laundette P Jones; Saijun Fan; Yiyu Zhang; Priscilla A Furth; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2005-08-18

8.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

Review 9.  Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Toxicol Pathol       Date:  2010-01-15       Impact factor: 1.902

10.  Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.

Authors:  Rui-Hong Wang; Yin Zheng; Hyun-Seok Kim; Xiaoling Xu; Liu Cao; Tyler Luhasen; Mi-Hye Lee; Cuiying Xiao; Athanassios Vassilopoulos; Weiping Chen; Kevin Gardner; Yan-Gao Man; Mien-Chie Hung; Toren Finkel; Chu-Xia Deng
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.